Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Core Viewpoint - Pharma Two B Ltd. and Hepion Pharmaceuticals, Inc. have announced the filing of a registration statement with the SEC for a proposed merger, which is expected to close in the fourth quarter of 2024, subject to various approvals and conditions [1][2][4]. Company Overview - Pharma Two B is a late-stage pharmaceutical company focused on developing innovative combination drugs for neurological disorders, particularly Parkinson's Disease, with its lead product candidate being P2B001 [6]. - Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company that has been developing treatments for chronic liver diseases, including non-alcoholic steatohepatitis and hepatocellular carcinoma [9]. Proposed Transaction - The merger transaction has been approved by the boards of directors of both companies and is contingent upon stockholder approval, regulatory approval, and the listing of Pharma Two B's shares on Nasdaq under the ticker symbol "PHTB" [4]. - The registration statement includes a proxy statement/prospectus related to the merger and provides essential information about both companies and the proposed transaction [2][13]. Product Information - P2B001 is an investigational combination of pramipexole and rasagiline, designed for the treatment of Parkinson's Disease, and has shown comparable benefits to marketed doses while minimizing side effects in clinical trials [7][8]. - Pharma Two B holds worldwide patents for the pharmaceutical composition and treatment method associated with P2B001 [8]. Financial and Legal Advisors - A.G.P./Alliance Global Partners is serving as the financial advisor to Hepion, while Laidlaw & Company (UK) Ltd. is acting as the financial advisor to Pharma Two B [5].